Navigation Links
CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
Date:9/11/2007

port the discovery and development of novel stem cell therapeutics for the heart. Work on the project is expected to start in October 2007.

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2006, there were 3.1 million outpatient visits to Cleveland Clinic, from every state and from more than 80 countries. There were more than 53,000 hospital admissions to Cleveland Clinic. Cleveland Clinic's Web site address is http://www.clevelandclinic.org.

About CellCyte Genetics

CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products.

For further information see: http://www.cellcyte.com.

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Safe Harbor Statement

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...rmaceuticals (SPI) has filed,an Investigational Ne...esting of a proprietary formulation of ebselen for...ss or ototoxicity. The oral capsule,containing ebs...ung cancer,and head and neck cancer patients recei...econd development program for SPI to enter clinica...
(Date:7/23/2008)...ma Inc., a company developing,breakthrough molecul...aphy,(PET) market, announced positive Phase I resu...r for myocardial perfusion imaging. BFPET is,Fluor...e Phase I clinical,development., BFPET is a PET i... the,heart (myocardial perfusion). Myocardial perf...
(Date:7/23/2008)...ode BioPharmaceutics, Inc.,an emerging biopharmac...results demonstrating the utility of their lead dr...hronic blood disorder paroxysmal nocturnal,hemoglo...ted at the XXII,International Complement Workshop ...nly treatment currently available for PNH patients...
(Date:7/23/2008)...Protein Therapeutics that Modulate Alter...ass., July 23 /- Taligen Therapeutics... growth plan with the,appointment of Abbie Celnike...lishment of its headquarters in Cambridge, Mass. D...under of the company who remains president., Unde...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 1Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 5Threepeat for HealthPus 21 4676 1NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 1NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 2NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 3Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 1Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 2Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 3Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 4Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 5
...2007 - Elixir,Pharmaceuticals, Inc., announced tod...he ability of Glufast(R) (mitiglinide calcium,hydr...ormin, to,manage glucose surges before and after m... for the American Diabetes,Association 67th Annual... is an insulin secretagogue that lowers postprandi...
...- CytRx Corporation,(NASDAQ:CYTR), a biopharmaceut...cialization of human therapeutics, today,reported ...y,announced double-blind, placebo-controlled, risi...ers with its drug candidate,arimoclomol. CytRx bel...se of arimoclomol in future clinical trials, inclu...
Other Medicine Technology:Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 2CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 3CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 4CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 5
(Date:7/25/2008)...S, July 25 /PRNewswire/ -- BeaconEquity.com announ...ing news today., Investors can view all of the da...aconEquity.com/m , Today,s Trade Alerts include: ...Brook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaM...R ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis I...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins ... -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ...d today that its subsidiary has commenced commerci...ules USP product in the 40mg,strength from its Dav...,with the launch, Watson has 180 days of marketing...
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...can be toughest for those trying to drop pounds, s...y News) -- Anyone who has avoided Monday morning w...e not a dieter,s friend. , Now, researchers hav...t weekends being their undoing: Most people do eat...lose weight. , "Weekend indulgences can wreak h...
Breaking Medicine News(10 mins):Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...pective study conducted by researchers from the Ge...rfs in ancient Egypt had received their much-deser...emains and other art forms demonstrated that dwarf...ical deformity. Infact, ancient Egyptians even wo...
...an woman was ecstatic that she and her daughter tr...mas in an intensive care unit // . Mariam Ameh’s ...ell after journeying to Cleveland's Rainbow Babies...e doctors removed a brain tumor the size of a grap...
...r Lloyd Johnston of the University of Michigan in ...e was a decrease in smoking in these students but ...ous painkillers // . The researchers found that al...g drugs. The increase in use of painkillers may be...
...abia is gearing up to face around 2.5 million Hajj...reening when they enter Saudi Arabia to all the Ha...ion//. World wide the threat of pandemic bird flu ...ns and spread of the virus is high in mass gatheri...
Other Medicine News:Health News:Respecting Dwarfs- A Lesson To Be Learnt From Ancient Egyptians 2Health News:Nigerian girl recovering well after removal of brain tumor 2
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: